Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreren
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Rapport
Vertraagde tijd Nasdaq  -  22:00:00 08-02-2023
7.200 USD   -6.74%
01/02Allogene Therapeutics, Inc. Presenteert gegevens over Dagger, een Next Generation AlloCAR T Platform Technologie
CI
25/01Allogene Therapeutics zegt dat preklinische resultaten DLL3 ondersteunen als potentiële behandeling voor longkanker
MT
25/01Allogene Therapeutics publiceert preklinische gegevens in klinisch kankeronderzoek ter ondersteuning van DLL3 als potentieel AlloCAR T™ doelwit voor kleincellige longkanker.
CI
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť ALLOGENE THERAPEUTICS, INC.
02/02Allogene Therapeutics Presents Data on Dagger, a Next Generation AlloCAR T Platform Tec..
AQ
01/02Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T&trade..
GL
01/02Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T&trade..
GL
25/01Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1..
AQ
25/01Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting..
GL
25/01Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting..
GL
24/01Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1..
GL
17/01Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
GL
04/01Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GL
04/01Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
AQ
03/01Allogene Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
03/01Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Resear..
GL
03/01Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Resear..
AQ
2022Relapsing Refractory Multiple Myeloma Pipeline as Novel and Extensive 60+ Therapies Lik..
AQ
2022Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across..
AQ
2022Allogene Therapeutics, Inc. : Other Events (form 8-K)
AQ
2022Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across..
GL
2022Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across..
GL
2022Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T Cells to ..
AQ
2022Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Ce..
GL
2022Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Ce..
AQ
2022Allogene Therapeutics To Host Research & Development Showcase and Participate in Five U..
GL
2022Allogene Therapeutics To Host Research & Development Showcase and Participate in Five U..
AQ
2022Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in M..
GL
2022Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in M..
AQ
2022ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
2022Allogene Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
2022Allogene Therapeutics : Q3 Earnings Snapshot
AQ
2022Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Invest..
GL
2022Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shangha..
AQ
2022Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shangha..
GL
2022Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shangha..
AQ
2022Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 202..
GL
2022Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 202..
GL
2022Allogene Therapeutics Launches CAR T Together, a First-of-its-Kind Initiative with Lead..
AQ
2022Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative wi..
GL
2022Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative wi..
AQ
2022Allogene Therapeutics Initiates Industry's First Allogeneic CAR T Phase 2 Trial
AQ
2022Allogene Therapeutics, Inc. : Other Events (form 8-K)
AQ
2022Allogene Therapeutics Initiates Industry's First Allogeneic CAR T Phase 2 Trial
GL
2022Allogene Stocks Fall as Servier Abandons Anti-CD19 Partnership
AQ
2022Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicin..
GL
2022Allogene Therapeutics : Current Report - Form 8-K
PU
2022Allogene Therapeutics, Inc. : Other Events (form 8-K)
AQ
2022Allogene Therapeutics : August 2022 Corporate Presentation
PU
2022Allogene Therapeutics : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
2022Allogene Therapeutics : Q2 Earnings Snapshot
AQ
2022ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
2022Allogene Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
2022Allogene Therapeutics Reports Second Quarter 2022 Financial Results
GL
2022Allogene Therapeutics Reports Second Quarter 2022 Financial Results
AQ
2022Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
GL
2022Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
GL
2022Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
GL
2022Allogene Therapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
2022Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Director..
GL
2022Allogene Therapeutics, Inc. : Submission of Matters to a Vote of Security Holders, Financi..
AQ
2022Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy ..
GL
2022Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy ..
AQ
2022Allogene Therapeutics : ALLO May 2022 Corporate Presentation
PU
2022Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
GL
2022Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
AQ
2022Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
2022Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
2022ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
2022Allogene Therapeutics : Q1 Earnings Snapshot
AQ
2022Allogene Therapeutics, Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
2022Allogene Therapeutics Reports First Quarter 2022 Financial Results
GL
2022Allogene Therapeutics Reports First Quarter 2022 Financial Results
AQ
2022Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb..
AQ
2022Allogene Therapeutics Appoints Susan Lundeen as Chief People Officer
GL
2022Allogene Therapeutics to Report First Quarter 2022 Financial Results on May 4, 2022
AQ
2022Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First Turb..
AQ
2022Allogene Therapeutics : ALLO April 2022 Corporate Presentation
PU
2022Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T Candidate Ta..
AQ
1  2  3  4Volgende
Volgende evenement op ALLOGENE THERAPEUTICS, INC.